MOUNTAIN VIEW: Materna Medical Inc., a women’s pelvic health company, has secured additional funding in its ongoing $20 million Series B2 financing round.
New investors GLIN Impact Capital, Wealthing VC Club and Citrine Angels joined the round, led by InnovaHealth Partners and existing backers Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund and Golden Seeds.
The company also announced the commercial name of its second product, Ellora™, previously called Materna Prep, which aims to improve care during labor and delivery.
“We’re thrilled to welcome these new investors and unveil Ellora™, designed to redefine labor and delivery standards,” said CEO Tracy MacNeal. “More than 20 top U.S. hospitals have partnered with us on the EASE trial for Ellora™, which will support our FDA De Novo submission this summer.”
Materna Medical, based in Mountain View, California, focuses on innovations in women’s pelvic health. Its first product, Milli™, is an FDA-cleared vaginal dilator for vaginismus and related conditions. The company is also developing Ellora™ to reduce pelvic floor injuries during childbirth, currently under study in the EASE trial.
Materna Medical is a women’s health company addressing unmet needs in OBGYN care. Its products include Milli™, an over-the-counter vaginal dilator, and the investigational device Ellora™, aimed at improving labor and delivery outcomes. The company’s mission is to advance pelvic health through medical innovation.